In This Article:
Argus notes that Emerson (EMR) shares have underperformed the broad market over the past three months, falling 14% while the S&P 500 declined 7%, despite the fact that Emerson reported fiscal Q1 EPS that rose 13% from a year earlier and exceeded analysts’ expectations. The firm, which is maintaining its Buy rating with a price target of $148, views the relative weakness in the shares as a buying opportunity, the analyst tells investors.
Don't Miss Our End of Quarter Offers:
-
Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks.
-
Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EMR: